Management of Metastatic Hormone-Sensitive Prostate Cancer in the Era of Treatment Intensification
Dr. Viscuse presents a comprehensive overview of the evolving treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC), emphasizing the importance of personalized therapy. Dr. Viscuse outlines the historical context of androgen deprivation therapy (ADT) as the foundation of advanced prostate cancer treatment. While ADT alone has shown survival benefits, the advent of treatment intensification has significantly altered the therapeutic approach.